﻿ In contrast to systemic and topical immune suppression, localized gene delivery of HLA-G may significantly reduce the off-target risks and establish a long-term anti-inflammatory effect that would be an effective, novel therapeutic strategy for refractory and recurrent uveitis as well as other ocular autoimmune inflammatory diseases in both human and veterinary patients. The gene discussed is HLA-G; the disease is uveitis.